Loading clinical trials...
Loading clinical trials...
A Global PRospective, Multi-cEnter, ObServational Post-markeT Study tO Assess shoRt, Mid and Long-term Effectiveness and Efficiency of VNS Therapy® as Adjunctive Therapy in reaL-world patIents With diFficult to Treat dEpression.
The primary objective of this study is to assess short, mid and long-term clinical outcomes in patients with difficult to treat depression (such as patients with treatment resistant depression) treated with Vagus Nerve Stimulation (VNS) Therapy as adjunctive therapy.
The population under study comprises a real-world patient population with difficult to treat depression: patients diagnosed with unipolar or bipolar disorder with chronic or recurrent depression who fail to achieve an adequate response to standard psychiatric management. The diagnosis of depression and comorbid disorders will be determined based on the Mini International Neuropsychiatric Interview (MINI). A minimum of five hundred (500) patients will be implanted with a VNS Therapy System and up to eighty (80) sites may participate in this study. Enrollment will take 8 years, based on competitive enrollment. For each subject a baseline visit will occur between 1 and 6 weeks before implant. Once implanted with the device, subjects will be followed-up for a minimum of 36 months and a maximum of 60 months. The study may stop when the last subject has reached the 36 months follow-up.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
AKH Allgemeines Krankenhaus der Stadt Wien
Vienna, Austria
KU Leuven
Leuven, Belgium
Sozialstiftung Bamberg - Klinikum am Bruderwald
Bamberg, Germany
Universitätsklinikum Bonn
Bonn, Germany
Universitätsklinikum Köln
Cologne, Germany
LVR-Hospital Essen
Essen, Germany
Universitätsklinikum Frankfurt
Frankfurt, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Universitätsmedizin Göttingen
Göttingen, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Start Date
December 14, 2017
Primary Completion Date
December 1, 2029
Completion Date
December 1, 2031
Last Updated
January 26, 2026
500
ESTIMATED participants
Vagal Nerve Simulation (VNS) Therapy
DEVICE
Lead Sponsor
LivaNova
NCT04480918
NCT04041479
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06895863